OTX-TKI

DRUG4 trials

Sponsors

Ocular Therapeutix, Inc.

Conditions

Neovascular Age-Related Macular Degeneration (nAMD)Neovascular Age-related Macular DegenerationNon-proliferative Diabetic Retinopathy

Phase 1

CLN-0046: Treatment of AMD Subjects With OTX-TKI

CompletedNCT03630315

Ocular Therapeutix, Inc.Neovascular Age-related Macular Degeneration

Start: 2019-02-18End: 2024-01-10Updated: 2024-07-10

Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy

Ocular Therapeutix, Inc.Non-proliferative Diabetic Retinopathy

Start: 2023-01-15End: 2024-12-31Target: 21Updated: 2023-12-08

Phase 3

Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

Active, not recruitingNCT06495918

Ocular Therapeutix, Inc.Neovascular Age-related Macular Degeneration

Start: 2024-11-27End: 2027-01-08Target: 825Updated: 2025-06-17

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

Not yet recruitingNCT07516132

Ocular Therapeutix, Inc.Neovascular Age-Related Macular Degeneration (nAMD)

Start: 2026-04-01End: 2030-08-01Target: 850Updated: 2026-04-07